Media

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Oncopeptides – European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

Positrigo Reaches Final of the Swiss Medtech Award 2026

First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat

Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Intervacc presents to the capital market on three occasions in March